E
FSTX

Ergoteles’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Ergoteles’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-148,354
Closed -$760K – 2084
2022
Q3 		$760K Buy
148,354
+40,934
+38% +$257K 0.03% 598
2022
Q2 		$672K Buy
+107,420
New +$362K 0.02% 708

Other funds holding FSTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's FSTX Position: Q4 2022 in Review

Ergoteles sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2022, closing a stake of 148,354 shares — an estimated $760K sold.

Ergoteles first reported a position in FSTX in Q2 2022 and held it in 2 quarters. The position peaked at $760K in Q3 2022. 59 funds tracked by Wall St. Rank hold FSTX as of Q4 2022.

  • Ergoteles reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 148,354 F-star Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $760K.
  • Ergoteles first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's F-star Therapeutics, Inc. Common Stock position peaked at $760K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.